Finan, C;
Gaulton, A;
Kruger, FA;
Lumbers, RT;
Shah, T;
Engmann, J;
Galver, L;
... Casas, JP; + view all
(2017)
The druggable genome and support for target identification and validation in drug development.
Science Translational Medicine
, 9
(383)
, Article eaag1166. 10.1126/scitranslmed.aag1166.
Preview |
Text (Accepted manuscript)
The druggable genome and support for target identification and validation in drug development_AAM.pdf - Accepted Version Download (2MB) | Preview |
Preview |
Text (Supplementary figures and tables)
Casas Romero_The druggable genome and support_supp_.pdf - Accepted Version Download (11MB) | Preview |
Abstract
Target identification (determining the correct drug targets for a disease) and target validation (demonstrating an effect of target perturbation on disease biomarkers and disease end points) are important steps in drug development. Clinically relevant associations of variants in genes encoding drug targets model the effect of modifying the same targets pharmacologically. To delineate drug development (including repurposing) opportunities arising from this paradigm, we connected complex disease- and biomarker-associated loci from genome-wide association studies to an updated set of genes encoding druggable human proteins, to agents with bioactivity against these targets, and, where there were licensed drugs, to clinical indications. We used this set of genes to inform the design of a new genotyping array, which will enable association studies of druggable genes for drug target selection and validation in human disease.
Archive Staff Only
 |
View Item |
